First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) plus /- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

被引：9
|
作者：
Miles, D. [1 ]
Cameron, D. [2 ,3 ]
Bondarenko, I. [4 ]
Lyudmila, M. [5 ]
Alcedo, J. C. [6 ]
Lopez, R. I. [7 ,8 ]
Im, S. A. [9 ]
Canon, J. L. [10 ]
Shparyk, Y. [11 ]
Yardley, D. [12 ,13 ]
Masuda, N. [14 ]
Ro, J. [15 ]
Hubeaux, S. [16 ]
Quah, C. [17 ]
Bais, C. [17 ]
O'Shaughnessy, J. [18 ,19 ]
机构：
[1] Mt Vernon Canc Ctr, Med Oncol, Northwood, Middx, England
[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[3] NHS Lothian, Canc Serv, Med Oncol, Edinburgh, Midlothian, Scotland
[4] Dnepropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnepropetrovsk, Ukraine
[5] NN Blokhin Canc Ctr, Med Oncol, Moscow, Russia
[6] Ctr Hemato Oncol Paitilla, Med Oncol, Panama City, Panama
[7] Natl Oncol Inst, Panama City, Panama
[8] Ctr Oncol Punta Pacifica, Med Oncol, Panama City, Panama
[9] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[10] Grand Hop Charleroi, Oncol & Haematol, Charleroi, Belgium
[11] Lviv State Oncol Reg Treatment & Diagnost Ctr, Med Oncol, Lvov, Ukraine
[12] Sarah Cannon Res Inst, Nashville, TN USA
[13] Tennessee Oncol, Med Oncol, Nashville, TN USA
[14] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan
[15] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea
[16] F Hoffmann La Roche Ltd, Biostat, Pharma Dev, Basel, Switzerland
[17] Genentech Inc, Global Dev BioOncol, San Francisco, CA 94080 USA
[18] Baylor Charles A Sammons Canc Ctr, US Oncol, Dallas, TX USA
[19] Texas Oncol, Med Oncol, Dallas, TX USA
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30816-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1866
引用
收藏
页码：S287 / S288
页数：2
相关论文
共 50 条
  • [1] Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer
    Miles, David
    Cameron, David
    Hilton, Magalie
    Garcia, Josep
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 153 - 155
  • [2] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
    Miles, David
    Cameron, David
    Bondarenko, Igor
    Manzyuk, Lyudmila
    Alcedo, Juan Carlos
    Lopez, Roberto Ivan
    Im, Seock-Ah
    Canon, Jean-Luc
    Shparyk, Yaroslav
    Yardley, Denise A.
    Masuda, Norikazu
    Ro, Jungsil
    Denduluri, Neelima
    Hubeaux, Stanislas
    Quah, Cheng
    Bais, Carlos
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 146 - 155
  • [3] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [4] MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer
    Miles, David
    Faoro, Leonardo
    Wang, Yan V.
    O'Shaughnerary, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Biomarker (BM) results from MERiDiAN, a double-blind placebo (PLA)-controlled randomized phase 3 trial of 1st-line paclitaxel (PAC) with or without bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)
    Das Thakur, M.
    Bais, C.
    Estay, I.
    Vaidyanathan, R.
    O'Shaughnessy, J.
    Cameron, D.
    Hubeaux, S.
    Quah, C.
    Miles, D.
    CANCER RESEARCH, 2016, 76
  • [6] Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI)
    Yardley, Denise Aysel
    Bosserman, Linda D.
    Peacock, Nancy Walker
    Favret, Anne
    Morgan, Susan Kay
    Priego, Victor M.
    Bass, J. David
    Griner, Paula L.
    Burris, Howard A.
    Hainsworth, John D.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Real-world effectiveness and safety of first-line bevacizumab (BEV) plus paclitaxel (PAC) in > 2000 patients (pts) with HER2-negative metastatic breast cancer (mBC)
    Mueller, V.
    Dank, M.
    de Ducla, S.
    Mitchell, L.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) In Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study
    Foerster, F.
    Aktas, B.
    Geberth, M.
    Tschechne, B.
    Schneeweiss, A.
    Salat, C.
    Tesch, H.
    Welslau, M.
    Schmidt, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S352
  • [10] A DOUBLE-BLIND, RANDOMISED, PLACEBO (PL)-CONTROLLED, PHASE 2B STUDY EVALUATING FIRST-LINE USE OF SORAFENIB (SOR) IN COMBINATION WITH PACLITAXEL (PAC) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (BC)
    Gradishar, W. J.
    Kaklamani, V.
    Sahoo, T. P.
    Lokanatha, D.
    Raina, V.
    Bondarde, S.
    Jain, M.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 61 - 61
12345